Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (251-260 of 531) with videos related to

Pageof 54
Sort By:
Infection and Immunity|July 19, 2000
Influence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditisR C Mercier, M J Rybak, A S Bayer, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1996
Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsA S Benko, D M Cappelletty, J A Kruse, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1987
Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicinM J Rybak, J J Frankowski, D J Edwards, et al.
The Journal of Antimicrobial Chemotherapy|January 13, 2009
Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptidesSteven N Leonard, Kerri L Rossi, Karly L Newton, et al.
Antimicrobial Agents and Chemotherapy|April 3, 2013
Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect"Brian J Werth, Molly E Steed, Glenn W Kaatz, et al.
Antimicrobial Agents and Chemotherapy|March 12, 2014
A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureusKatie E Barber, Brian J Werth, John P McRoberts, et al.
Infectious Diseases and Therapy|March 10, 2019
Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, PlazomicinJacinda C Abdul-Mutakabbir, Razieh Kebriaei, Sarah C J Jorgensen, et al.
Infectious Diseases and Therapy|April 2, 2018
Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic PropertiesSarah C J Jorgensen, Nicholas J Mercuro, Susan L Davis, et al.
Antibiotics (Basel, Switzerland)|November 4, 2020
The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA-Salvaging the Gold Standards with Combination TherapyTaylor Morrisette, Sara Alosaimy, Jacinda C Abdul-Mutakabbir, et al.
Pharmacotherapy|October 17, 2020
Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative PathogensJacinda C Abdul-Mutakabbir, Sara Alosaimy, Taylor Morrisette, et al.
Pageof 54

Showing results (251-260 of 531) with videos related to

Sort By:
Pageof 54
Infection and Immunity|July 19, 2000
Influence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditisR C Mercier, M J Rybak, A S Bayer, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1996
Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsA S Benko, D M Cappelletty, J A Kruse, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1987
Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicinM J Rybak, J J Frankowski, D J Edwards, et al.
The Journal of Antimicrobial Chemotherapy|January 13, 2009
Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptidesSteven N Leonard, Kerri L Rossi, Karly L Newton, et al.
Antimicrobial Agents and Chemotherapy|April 3, 2013
Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect"Brian J Werth, Molly E Steed, Glenn W Kaatz, et al.
Antimicrobial Agents and Chemotherapy|March 12, 2014
A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureusKatie E Barber, Brian J Werth, John P McRoberts, et al.
Infectious Diseases and Therapy|March 10, 2019
Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, PlazomicinJacinda C Abdul-Mutakabbir, Razieh Kebriaei, Sarah C J Jorgensen, et al.
Infectious Diseases and Therapy|April 2, 2018
Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic PropertiesSarah C J Jorgensen, Nicholas J Mercuro, Susan L Davis, et al.
Antibiotics (Basel, Switzerland)|November 4, 2020
The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA-Salvaging the Gold Standards with Combination TherapyTaylor Morrisette, Sara Alosaimy, Jacinda C Abdul-Mutakabbir, et al.
Pharmacotherapy|October 17, 2020
Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative PathogensJacinda C Abdul-Mutakabbir, Sara Alosaimy, Taylor Morrisette, et al.
Pageof 54